ENTITY
Alphamab Co Ltd

Alphamab Co Ltd (9966 HK)

103
Analysis
Health CareChina
Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.
more
03 Feb 2020 13:37

Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising

Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...

Logo
614 Views
Share
16 Jan 2020 14:57

2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
531 Views
Share
08 Jan 2020 17:38

2019 Hong Kong IPO Analytics: Highlight of Brokers’ and Sectors’ Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
677 Views
Share
bullishAlphamab Co Ltd
11 Dec 2019 18:18

Alphamab Oncology: Trading Debut, Valuation Scenario Analysis

Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
499 Views
Share
bullishAlphamab Co Ltd
11 Dec 2019 17:20

Alphamab (康宁杰瑞) IPO: Allocation and Buy-Level for the Hot Deal

Alphamab, the leading bispecific antibodies player in China, raised USD 220 million at HKD 10.2 per share. In this insight, we will cover the...

Logo
498 Views
Share
x